التفاصيل البيبلوغرافية
العنوان:
Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma
المؤلفون:
Matt Kalaycio , Betty K. Hamilton , Melissa Yurch , Hien Liu , Ronald Sobecks , Navneet S. Majhail , Steven Andresen , Brad Pohlman , Robert M. Dean , Donna Corrigan , Kelly Cherni , Moaath Mustafa Ali , Lisa Rybicki , Brian J. Bolwell
المصدر:
Hematology/oncology and stem cell therapy . 11(4)
سنة النشر:
2017
مصطلحات موضوعية:
Oncology , Male , medicine.medical_specialty , Transplantation Conditioning , Cyclophosphamide , medicine.medical_treatment , education , Administration, Oral , Hematopoietic stem cell transplantation , Transplantation, Autologous , Internal medicine , Plasma Cell Myeloma , medicine , Humans , Busulfan , Transplant Conditioning , Hematopoietic cell , business.industry , Hematopoietic Stem Cell Transplantation , Hematology , General Medicine , humanities , Transplantation , Bone transplantation , Administration, Intravenous , Female , business , Multiple Myeloma , Immunosuppressive Agents , medicine.drug
الوصف:
s / Biol Blood Marrow Transplant 19 (2013) S178eS193 S190 (calculated from diagnosis) was 131 months and the fiveyear overall survival rate was 55.5%. Conclusions: In our experience, ASCT was associated with excellent disease control and outcomes in patients with relapsed refractory LPHL.
تدمد:
2589-0646
الوصول الحر:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49af63f3c968f6d77aa763106356db13Test https://pubmed.ncbi.nlm.nih.gov/29705567Test
حقوق:
OPEN
رقم الانضمام:
edsair.doi.dedup.....49af63f3c968f6d77aa763106356db13
قاعدة البيانات:
OpenAIRE
